Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTPHEX3)

DTT Name Ceramide glucosyltransferase (UGCG)
Synonyms UGCG; UDP-glucose:N-acylsphingosine D-glucosyltransferase; UDP-glucose ceramideglucosyltransferase; Glucosylceramide synthase; GLCT-1
Gene Name UGCG
DTT Type
Successful target
 [1]
BioChemical Class
Hexosyltransferase
UniProt ID
CEGT_HUMAN
TTD ID
T14908
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 2.4.1.80
Sequence
MALLDLALEGMAVFGFVLFLVLWLMHFMAIIYTRLHLNKKATDKQPYSKLPGVSLLKPLK
GVDPNLINNLETFFELDYPKYEVLLCVQDHDDPAIDVCKKLLGKYPNVDARLFIGGKKVG
INPKINNLMPGYEVAKYDLIWICDSGIRVIPDTLTDMVNQMTEKVGLVHGLPYVADRQGF
AATLEQVYFGTSHPRYYISANVTGFKCVTGMSCLMRKDVLDQAGGLIAFAQYIAEDYFMA
KAIADRGWRFAMSTQVAMQNSGSYSISQFQSRMIRWTKLRINMLPATIICEPISECFVAS
LIIGWAAHHVFRWDIMVFFMCHCLAWFIFDYIQLRGVQGGTLCFSKLDYAVAWFIRESMT
IYIFLSALWDPTISWRTGRYRLRCGGTAEEILDV
Function Catalyzes the first glycosylation step in glycosphingolipid biosynthesis, the transfer of glucose to ceramide. May also serve as a "flippase".
KEGG Pathway
Sphingolipid metabolism (hsa00600 )
Metabolic pathways (hsa01100 )
Reactome Pathway
Glycosphingolipid metabolism (R-HSA-1660662 )
BioCyc Pathway
MetaCyc:HS07494-MON

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eliglustat tartrate DMSRZAO Metabolic disorder 5C50-5D2Z Approved [2]
Miglustat DM5J64S Niemann-Pick disease type C Approved [1]
------------------------------------------------------------------------------------
1 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Venglustat DMLPEZS Fabry disease 5C56.01 Phase 2 [3]
------------------------------------------------------------------------------------
1 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
N-butylgalactonojirimycin DMB06TA Discovery agent N.A. Investigative [4]
------------------------------------------------------------------------------------

References

1 Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther. 2007 Aug;29(8):1645-54.
2 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis. J Biol Chem. 2007 Nov 9;282(45):32655-64.